Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P15586
UPID:
GNS_HUMAN
Alternative names:
Glucosamine-6-sulfatase
Alternative UPACC:
P15586; B4DYH8; Q53F05
Background:
N-acetylglucosamine-6-sulfatase, also known as Glucosamine-6-sulfatase, plays a crucial role in the lysosomal degradation of heparan sulfate. This enzyme's activity is essential for the normal turnover of glycosaminoglycans in the body.
Therapeutic significance:
Mutations in N-acetylglucosamine-6-sulfatase are directly linked to Mucopolysaccharidosis 3D, a severe neurological disorder. Understanding the enzyme's function could lead to breakthrough therapies for this debilitating disease.